You have read all your free articles, to continue reading subscribe to read the rest of this content.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy 100/3.6. Xultophy 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled Already a subscriber Login…
Karolinska Development has published its Interim Report for the period January to March 2016. Significant events during Karolinska Development's first quarter this year include Aprea raising SEK 437 million in a Series B financing round from a syndicate of specialist international life science Already a subscriber Login You have read all your…
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patiAlready a subscriber Login…
Medivir announces that the Investigational New Drug (IND) application for MIV-711 has been accepted and the IND is now open with the FDA (U.S. Food and Drug Administration). "We are very pleased to have received FDA acceptance for our IND. This is a regulatory milestone for MIV-711 and enables clAlready…
